UNSPSC 51372313: Piminodine

This classification denotes an opioid receptor agonist with the molecular formula C23H30N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 3IIX447HWS chemically known as 4-piperidinecarboxylic acid, 4-phenyl-1-(3-(phenylamino)propyl)-, ethyl ester but generally known as piminodine, which bears US NIH Compound Identifier 21950. European Medicines Agency schedules Piminodine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09844MIG.

UNSPSC 51372313 Piminodine (Commodity) covers pharmaceutical product procurement by state and local governments, though recent activity shows state and local agencies sourcing a broader range of pharmaceutical and over-the-counter products rather than piminodine specifically. The kinds of products being solicited include naloxone and drug deactivation systems for public health interventions, generic multi-source pharmaceuticals with specific National Drug Codes through cooperative purchasing arrangements, and exploratory direct-to-manufacturer prescription programs. Issuing bodies range from county health departments (Seminole County, Florida) to state health and human services commissions (Texas Health and Human Services Commission) to multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and participating jurisdictions). Solicitations are structured as competitive bids (IFB), requests for information (RFI) to gather market intelligence, and requests for proposal (RFP) for formal contract awards. Vendors typically must meet federal compliance requirements including Drug Supply Chain Security Act certification, current Good Manufacturing Practices, FDA approval, E-Verify employment verification, and substantial insurance coverage (commercial general liability ranging from $2 million to $5 million per occurrence depending on the scope).

Recent activity concentrates in Florida and Minnesota, with Texas conducting exploratory procurement planning. The most recent opportunity is Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, on a two-year contract with one-year renewal option. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with awards effective July 1, 2026 and pricing evaluation weighted 75 percent on competitiveness. The Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026) to explore vendor capacity for direct-to-manufacturer prescription programs as a preliminary market-intelligence phase before issuing a formal RFP. Vendor responses demonstrate that state and local pharmaceutical procurement emphasizes supply chain transparency, competitive pricing, and compliance with federal drug security and manufacturing standards.